POP Biotechnologies

Executive Summary

POP Biotechnologies is a privately held US biotech company founded in 2015, focused on developing nanomedicine platforms based on its proprietary porphyrin-phospholipid (PoP) liposome technology. The company's platform aims to enhance vaccine efficacy and enable targeted cancer therapies by improving drug delivery and immune activation. With a strong intellectual property portfolio and a versatile platform, POP Biotechnologies addresses critical needs in oncology and infectious diseases, positioning itself as a potential partner for larger pharmaceutical companies. However, as a private, early-stage company with no disclosed funding rounds or clinical-stage assets, the company faces typical risks of preclinical development, including technical hurdles and capital requirements.

Upcoming Catalysts (preview)

• Q3 2027Initiating Phase 1 trial for lead oncology candidate30% success
• Q4 2026Securing Series A financing or strategic partnership50% success
• Q2 2026Publication of preclinical PoP vaccine data in infectious disease70% success